PATENT CLAIM ANALYSIS

Application Number: 16066836
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2019-01
Patent Classification: ["424", "450000"]

Abstract:
Compositions and methods for making and using proliposomal and liposomal formulations of chemotherapeutic agents are disclosed. The proliposomal and liposomal formulations of chemotherapeutics, as well as medicaments and dosage forms that include such formulations, can be used with treatment regimens for bladder cancer and urothelial cancer. Hence, the formulations, medicaments, and dosage forms of the invention are suitable to treat bladder cancers by intravesical administration and to treat urothelial cancers. The formulations according to the invention include (a) a taxane (e.g., paclitaxel, docetaxel) or cisplatin, (b) a first phospholipid, dipalmitoyl phosphatidylcholine (DMPC), and (c) a second phospholipid, dimyrsityl phosphatidyl glycerol sodium (DMPG). The proliposomal formulations form liposomes upon contact with an aqueous vehicle.

Claim (Index 18):
The proliposomal powder dispersion according to  claim 17 , wherein the taxane is paclitaxel, and the weight ratios of (a):(b):(c) are (1):(1.3-3.8):(0.4-1.5).

Metadata:
- Claim Count in Document: 2.0
- Percentile: 94.0
- Lexical Diversity: 1.88
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14149227', '15268917', '12436697', '15250169', '13779625']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7351982841980295
- 35 USC 102 Novelty (BERT): 0.5009364592168125
- Combined Prediction Score: 0.7117721016999077
- Mean Citation Score: 247.325382
- Max Citation Score: 251.29027
- Similarity Product: 183.0247327631306

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test